Skip to main content

Table 1 Baseline characteristics of study participants

From: Intravenous artesunate plus Artemisnin based Combination Therapy (ACT) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial

Characteristic AS + DP
N = 79
AS + AL
N = 71
QNN + DP
N = 71
QNN + AL
N = 79
Female (%) 36 (45.6) 36 (50.7) 24 (33.8) 37 (46.8)
Age in monthsa 17 (11–26) 16 (10–26) 17 (13–26) 18 (13–26)
Weight (kgs)a 9.5 (8–11.5) 9 (8.1–11) 9.8 (8.8–11) 9.2 (8.4–11)
Temperature (degrees Centigrade)a 38.8 (37.7–39.5) 39.1 (37.7–39.5) 39.1 (37.3–39.5) 38.6 (37.5–39.6)
Parasite density per uL, log10 copiesa 4.82 (4.29–5.10) 4.79 (4.38–5.02) 4.72 (4.19–5.00) 4.73 (4.17–5.03)
Complications at admission, n (%)
 Hemoglobin (mg/dL)a 9.1 (7.9–10.5) 9.2 (8.4–10.6) 9.3 (8.4–10.4) 9.4 (8.0–10.3)
 Total white blood cell count (a103/uL)a 9.6 (6.9–13.2) 9.2 (7.5–12.3) 9.4 (7.7–12.1) 10.0 (7.0–14.3)
 Random blood sugar (mmol/L)a 7.3 (6.3–8.3) 6.8 (6.4–8.3) 6.8 (5.7–8.3) 7.4 (6.25–8.25)
 History of repeated convulsions n (%) 6 (7.6%) 3 (4.2%) 8 (11.3%) 1 (1.3%)
 History of inability to feed 26 (33.0%) 24 (34.0%) 22 (31.0%) 29 (36.7%)
 Prostration (extreme weakness) 22 (27.9%) 15 (21.13%) 21 (29.58%) 21 (26.58%)
 Hemoglobinuria 0 0 2 (2.8%) 0
 Jaundice 2 (2.5%) 0 3 (4.2%) 3 (3.8%)
 Severe anemia 0 0 1 (3%) 2 (2.5%)
 Respiratory distress 2 (2.5%) 6 (8.5%) 3 (4.2%) 5 (6.3%)
 Impaired consciousness 0 0 1 (1.4%) 0
 Abnormal bleeding 2 (2.5%) 1 (1.4%) 0 1 (1.3%)
 Hypoglycemia 0 0 0 1 (1.3%)
  1. aValues are presented as medians (IQR)